Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Modifies ARMS License to BTG and DxS; New Deal Enables Shops to Outlicense Tech

NEW YORK, Jan. 9 (GenomeWeb News) - AstraZeneca modified its agreement with BTG and DxS over licenses for the Amplification Refractory Mutation System, the companies said today.


Under the improved agreement, BTG and DxS can grant licenses to ARMS and related technologies to other companies.


The original agreement, signed in March 2004, gave BTG and DxS intellectual property rights to commercialize the technology within the diagnostic and research markets.


ARMS is used to detect gene mutations and SNPs.


Details on the agreement were not disclosed.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.